Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Retreatment with talquetamab and pomalidomide in triple-class-BCMA-GPRC5D refractory myeloma.
Journal: British journal of haematology
Published: January 23, 2026
"Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT": comment from Galarza Fortuna et al.
Journal: Journal of thrombosis and haemostasis : JTH
Published: July 25, 2025
Response to: Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)".
Journal: Journal for immunotherapy of cancer
Published: May 09, 2025
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US.
Journal: JAMA network open
Published: March 20, 2025
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT).
Journal: Journal for immunotherapy of cancer
Published: March 06, 2025
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers.
Journal: JAMA network open
Published: July 18, 2024
Risk-adapted treatment in multiple myeloma: Does more make it merrier?
Journal: British journal of haematology
Published: July 16, 2024
Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma.
Journal: Diagnostics (Basel, Switzerland)
Published: June 10, 2024
Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMI.
Journal: JCO precision oncology
Published: May 23, 2024
Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.
Journal: JAMA network open
Published: May 02, 2024
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix.
Journal: Therapeutic advances in urology
Published: April 12, 2024
Last Updated: 09/26/2026